Evidence map of umbrella review by early menarche and subsequent health outcomes
| Certainty of evidencea . | Outcome . | RR (95% CI) . | SMD (95% CI) . | Direction . |
|---|---|---|---|---|
| High (convincing evidence; Class I) | Metabolic syndrome | 1.56 (1.33, 1.83) | Positive | |
| Endometrial cancer | 1.40 (1.17, 1.68) | Positive | ||
| T2DM/IGT | 1.30 (1.19, 1.42) | Positive | ||
| Breast cancerb | 1.19 (1.06, 1.33) | Positive | ||
| Death from all causes | 1.11 (1.03, 1.19) | Positive | ||
| Moderate (Highly suggestive evidence; Class II) | Obesity | 1.68 (1.53, 1.84) | Positive | |
| Gestational diabetes mellitus | 1.32 (1.09, 1.58) | Positive | ||
| Hypertension | 1.24 (1.20, 1.29) | Positive | ||
| Endometriosis | 1.22 (1.09, 1.37) | Positive | ||
| Ovarian cancer | 1.17 (1.04, 1.31) | Positive | ||
| Death from stroke | 1.05 (0.89, 1.25) | No (not significant) | ||
| Death from cardiovascular disease | 1.03 (0.82, 1.30) | No (not significant) | ||
| Serum fasting insulin (uIU/ml) | 0.52 (0.48, 0.57) | Positive | ||
| HOMA-IR | 0.27 (0.19,0.35) | Positive | ||
| Adult BMI (≥40 years) | 0.30 (0.28,0.32) | Positive | ||
| Adult BMI (<40 years) | 0.39 (0.36,0.43) | Positive | ||
| Systolic blood pressure | 0.05 (−0.08,0.17) | No (not significant) | ||
| Diastolic blood pressure | 0.01 (−0.10, 0.13) | No (not significant) | ||
| Low (suggestive evidence; Class III) | Death from ischemic heart disease | 1.19 (0.87, 1.63) | No (not significant) | |
| Asthma | 1.27 (1.08, 1.48) | Positive | ||
| Very low (weak evidence, Class IV) | Depression | 1.26 (0.75, 2.11) | No (not significant) |
| Certainty of evidencea . | Outcome . | RR (95% CI) . | SMD (95% CI) . | Direction . |
|---|---|---|---|---|
| High (convincing evidence; Class I) | Metabolic syndrome | 1.56 (1.33, 1.83) | Positive | |
| Endometrial cancer | 1.40 (1.17, 1.68) | Positive | ||
| T2DM/IGT | 1.30 (1.19, 1.42) | Positive | ||
| Breast cancerb | 1.19 (1.06, 1.33) | Positive | ||
| Death from all causes | 1.11 (1.03, 1.19) | Positive | ||
| Moderate (Highly suggestive evidence; Class II) | Obesity | 1.68 (1.53, 1.84) | Positive | |
| Gestational diabetes mellitus | 1.32 (1.09, 1.58) | Positive | ||
| Hypertension | 1.24 (1.20, 1.29) | Positive | ||
| Endometriosis | 1.22 (1.09, 1.37) | Positive | ||
| Ovarian cancer | 1.17 (1.04, 1.31) | Positive | ||
| Death from stroke | 1.05 (0.89, 1.25) | No (not significant) | ||
| Death from cardiovascular disease | 1.03 (0.82, 1.30) | No (not significant) | ||
| Serum fasting insulin (uIU/ml) | 0.52 (0.48, 0.57) | Positive | ||
| HOMA-IR | 0.27 (0.19,0.35) | Positive | ||
| Adult BMI (≥40 years) | 0.30 (0.28,0.32) | Positive | ||
| Adult BMI (<40 years) | 0.39 (0.36,0.43) | Positive | ||
| Systolic blood pressure | 0.05 (−0.08,0.17) | No (not significant) | ||
| Diastolic blood pressure | 0.01 (−0.10, 0.13) | No (not significant) | ||
| Low (suggestive evidence; Class III) | Death from ischemic heart disease | 1.19 (0.87, 1.63) | No (not significant) | |
| Asthma | 1.27 (1.08, 1.48) | Positive | ||
| Very low (weak evidence, Class IV) | Depression | 1.26 (0.75, 2.11) | No (not significant) |
BMI, body mass index; HOMA-IR, homeostatic model assessment for insulin resistance; IGT, impaired glucose tolerance; RR, relative risk; SMD, standard mean difference; T2DM, type 2 diabetes mellitus.
In accordance with previous umbrella reviews, we categorized the strength of the evidence.
This meta-analysis was performed at the individual level. We cannot calculate the Hartung–Knapp–Sidik–Jonkman method.
Evidence map of umbrella review by early menarche and subsequent health outcomes
| Certainty of evidencea . | Outcome . | RR (95% CI) . | SMD (95% CI) . | Direction . |
|---|---|---|---|---|
| High (convincing evidence; Class I) | Metabolic syndrome | 1.56 (1.33, 1.83) | Positive | |
| Endometrial cancer | 1.40 (1.17, 1.68) | Positive | ||
| T2DM/IGT | 1.30 (1.19, 1.42) | Positive | ||
| Breast cancerb | 1.19 (1.06, 1.33) | Positive | ||
| Death from all causes | 1.11 (1.03, 1.19) | Positive | ||
| Moderate (Highly suggestive evidence; Class II) | Obesity | 1.68 (1.53, 1.84) | Positive | |
| Gestational diabetes mellitus | 1.32 (1.09, 1.58) | Positive | ||
| Hypertension | 1.24 (1.20, 1.29) | Positive | ||
| Endometriosis | 1.22 (1.09, 1.37) | Positive | ||
| Ovarian cancer | 1.17 (1.04, 1.31) | Positive | ||
| Death from stroke | 1.05 (0.89, 1.25) | No (not significant) | ||
| Death from cardiovascular disease | 1.03 (0.82, 1.30) | No (not significant) | ||
| Serum fasting insulin (uIU/ml) | 0.52 (0.48, 0.57) | Positive | ||
| HOMA-IR | 0.27 (0.19,0.35) | Positive | ||
| Adult BMI (≥40 years) | 0.30 (0.28,0.32) | Positive | ||
| Adult BMI (<40 years) | 0.39 (0.36,0.43) | Positive | ||
| Systolic blood pressure | 0.05 (−0.08,0.17) | No (not significant) | ||
| Diastolic blood pressure | 0.01 (−0.10, 0.13) | No (not significant) | ||
| Low (suggestive evidence; Class III) | Death from ischemic heart disease | 1.19 (0.87, 1.63) | No (not significant) | |
| Asthma | 1.27 (1.08, 1.48) | Positive | ||
| Very low (weak evidence, Class IV) | Depression | 1.26 (0.75, 2.11) | No (not significant) |
| Certainty of evidencea . | Outcome . | RR (95% CI) . | SMD (95% CI) . | Direction . |
|---|---|---|---|---|
| High (convincing evidence; Class I) | Metabolic syndrome | 1.56 (1.33, 1.83) | Positive | |
| Endometrial cancer | 1.40 (1.17, 1.68) | Positive | ||
| T2DM/IGT | 1.30 (1.19, 1.42) | Positive | ||
| Breast cancerb | 1.19 (1.06, 1.33) | Positive | ||
| Death from all causes | 1.11 (1.03, 1.19) | Positive | ||
| Moderate (Highly suggestive evidence; Class II) | Obesity | 1.68 (1.53, 1.84) | Positive | |
| Gestational diabetes mellitus | 1.32 (1.09, 1.58) | Positive | ||
| Hypertension | 1.24 (1.20, 1.29) | Positive | ||
| Endometriosis | 1.22 (1.09, 1.37) | Positive | ||
| Ovarian cancer | 1.17 (1.04, 1.31) | Positive | ||
| Death from stroke | 1.05 (0.89, 1.25) | No (not significant) | ||
| Death from cardiovascular disease | 1.03 (0.82, 1.30) | No (not significant) | ||
| Serum fasting insulin (uIU/ml) | 0.52 (0.48, 0.57) | Positive | ||
| HOMA-IR | 0.27 (0.19,0.35) | Positive | ||
| Adult BMI (≥40 years) | 0.30 (0.28,0.32) | Positive | ||
| Adult BMI (<40 years) | 0.39 (0.36,0.43) | Positive | ||
| Systolic blood pressure | 0.05 (−0.08,0.17) | No (not significant) | ||
| Diastolic blood pressure | 0.01 (−0.10, 0.13) | No (not significant) | ||
| Low (suggestive evidence; Class III) | Death from ischemic heart disease | 1.19 (0.87, 1.63) | No (not significant) | |
| Asthma | 1.27 (1.08, 1.48) | Positive | ||
| Very low (weak evidence, Class IV) | Depression | 1.26 (0.75, 2.11) | No (not significant) |
BMI, body mass index; HOMA-IR, homeostatic model assessment for insulin resistance; IGT, impaired glucose tolerance; RR, relative risk; SMD, standard mean difference; T2DM, type 2 diabetes mellitus.
In accordance with previous umbrella reviews, we categorized the strength of the evidence.
This meta-analysis was performed at the individual level. We cannot calculate the Hartung–Knapp–Sidik–Jonkman method.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
